Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALM 201

Next Previous
Drug Profile

ALM 201

Alternative Names: ALM-201; FKBPL; FKBPL-derived anticancer peptides; Peptide anti-angiogenic compounds - Queens University Belfast/Almac Discovery

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Almac Discovery; Queens University Belfast
  • Developer Almac Discovery
  • Class Antineoplastics; Peptide fragments
  • Mechanism of Action Angiogenesis inhibitors; CD44 antigen modulators; Cell movement inhibitors; Immunophilin modulators; Microtubule protein modulators; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • No development reported Eye disorders; Ovarian cancer; Solid tumours

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Eye-disorders in United Kingdom (Ophthalmic)
  • 28 Aug 2021 No recent reports of development identified for phase-I development in Ovarian-cancer in United Kingdom (SC, Injection)
  • 28 Aug 2021 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top